PTO/SBr08s (08-03)
Approved for use through 07/31/2006 ONE 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
It is a collection of information unless it contains a valid OMS control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10734589		
	Filing Date		2003-12-15		
	First Named Inventor Govin		rindan		
	Art Unit		1642		
	Examiner Name	Brand	ion J. Fetterotf		
	Attorney Docket Numb	er	328884		

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number Kind Code1 Issue Date Name of Patentee or of cited Document			pplicant Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1									
If you wisi	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant		Releva	Columns,Lines who ant Passages or Re s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button		
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lin where Relevant Passages or Releva Figures Appear	76
	1	00/76551	wo			2000-12-21	KRATZ			
	2	0306943	EP			1989-03-15	SIVAM			
	3	0253202	EP			1988-01-20	HELLSTROM			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

F

Application Number		10734589		
Filing Date		2003-12-15		
First Named Inventor	Govin	dan		
Art Unit		1642		
Examiner Name	Brand	ion J. Fetterolf		
Attorney Docket Number		328884		

If you wisl	h to a	dd add	ional Foreign Pater	nt Document o	citation infor	mation pleas	e click the Add buttor	Add		
				NON-PATEN	T LITERAT	URE DOCU	MENTS	Remove		
Examiner Initials*	Cite No	(book		serial, sympo	sium, catalo		article (when approp , pages(s), volume-is			Т
	1	Metho					bicin Prepared with Bra Bioconjugate Chem. 19			
	2		, RAVI V., "Immunoci ch 52(1992) 1 Janua				: Promising Anticancer 0	Drugs* 617	5 Cancer	
	3		EL, NED D., et al., "A 430 XP-000983437	Novel Heterob	offunctional Lir	nker for Formy	of to Thiol Coupling" Bio	conjugate C	hem. 1991,	
	4		NSON-BUSZA, GAIL n in Oncology 1992, 4			very of biologic	and other antineoplas	tic agents" (Current	
If you wis	h to a	dd add	ional non-patent lite	erature docum	nent citation	information p	please click the Add I	outton A	dd	_
				EXA	AMINER SIG	SNATURE				
Examiner	Signa	ture					Date Considered			

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10734589		
Filing Date		2003-12-15		
First Named Inventor	Govin	ndan		
Art Unit		1642		
Examiner Name	Brand	ion J. Fetteroff		
Attorney Docket Number		328884		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appro	priate selection(s	s):
---------------	----------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Rita P. Sanzgiri/	Date (YYYY-MM-DD)	2007-03-19
Name/Print	Rita P. Sanznin	Registration Number	59846

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.